PETV PetVivo Holdings, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1512922 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.5%
TTM net income YoY0.2%
TTM EPS YoY18.9%
Revenue 3-yr CAGR4.4%
Net income 3-yr CAGR—
Margins
Gross margin70.3%
Operating margin-796.7%
Net margin-798.7%
FCF margin-386.1%
EBITDA margin-769.4%
Returns
ROE-433.2%
ROA-235.4%
ROIC (approx.)-424.0%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets107.4%
Debt / equity—
Current ratio0.31x
Interest coverage-394.93x
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio-122.2%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $212,806 | $337,572 | $254,715 | $286,108 | $303,284 | $297,500 | $224,750 | $583,313 |
| Cost of revenue | $16,731 | $114,255 | $51,460 | $141,396 | $83,226 | $110,774 | $42,024 | $61,497 |
| Gross profit | $196,075 | $223,317 | $203,255 | $144,712 | $220,058 | $186,726 | $182,726 | $521,816 |
| R&D expense | $322,296 | $233,419 | $490,095 | $322,991 | $261,433 | $340,513 | $358,608 | $371,953 |
| SG&A expense | $921,321 | $967,442 | $775,624 | $1.25M | $1.24M | $1.07M | $1.14M | $1.18M |
| Operating income | -$1.93M | -$1.61M | -$2.96M | -$2.19M | -$2.07M | -$1.84M | -$2.08M | -$1.76M |
| Interest expense | $15,526 | $5,039 | $1,447 | $0 | $179,183 | $121,808 | $5,677 | $461 |
| Pretax income | -$1.95M | -$1.61M | -$2.96M | -$2.19M | -$2.24M | -$2.31M | -$2.42M | -$1.76M |
| Net income | -$1.95M | -$1.61M | -$2.96M | -$2.19M | -$2.24M | -$2.31M | -$2.42M | -$1.76M |
| EBITDA | -$1.92M | -$1.47M | -$2.83M | -$2.18M | -$2.05M | -$1.73M | -$2.00M | -$1.73M |
| EPS (basic) | -0.05 | -0.05 | — | -0.07 | -0.09 | -0.10 | — | -0.09 |
| EPS (diluted) | -0.05 | -0.05 | — | -0.07 | -0.09 | -0.10 | — | -0.09 |
| Weighted avg. shares (diluted) | 38.02M | 37.06M | — | 33.67M | 27.58M | 24.30M | — | 20.63M |
| Banking | ||||||||
| Net interest income | — | — | — | — | — | — | -$329,947 | -$24,378 |
| Balance sheet | ||||||||
| Cash & equivalents | $16,287 | $122,633 | $200,782 | $18,164 | $767,914 | $3.30M | $227,689 | $28,891 |
| Short-term investments | — | — | $150,000 | — | — | — | $150,000 | — |
| Receivables | $32,417 | $83,792 | $100,843 | $29,862 | $137,999 | $25,948 | $60,573 | $493,121 |
| Inventory | $314,818 | $451,334 | $538,366 | $605,390 | $578,293 | $529,342 | $323,504 | $353,307 |
| Current assets | $697,545 | $941,019 | $1.71M | $1.38M | $2.11M | $4.40M | $5.61M | $1.23M |
| PP&E, net | $447,559 | $447,089 | $448,881 | $463,630 | $482,885 | $487,618 | $766,874 | $770,267 |
| Intangibles | $20,000 | $20,000 | $20,509 | $20,967 | $21,624 | $22,494 | $23,725 | $25,104 |
| Total assets | $2.15M | $2.67M | $3.58M | $4.38M | $5.26M | $6.89M | $9.34M | $3.11M |
| Current liabilities | $2.26M | $1.31M | $1.38M | $988,421 | $1.05M | $3.12M | $4.32M | $2.94M |
| Total liabilities | $2.31M | $1.31M | $1.38M | $997,404 | $1.08M | $3.16M | $5.12M | $3.81M |
| Shareholders' equity | -$159,093 | $1.36M | $2.20M | $3.38M | $4.18M | $2.97M | $4.22M | -$694,781 |
| Shares outstanding | 38.13M | 37.59M | 35.85M | 34.45M | 32.95M | 24.40M | 24.18M | 21.25M |
| Cash flow statement | ||||||||
| Operating cash flow | -$947,041 | -$965,779 | -$812,382 | -$1.47M | -$2.19M | -$1.63M | -$1.23M | -$961,216 |
| Capital expenditure | $14,305 | $12,370 | $0 | -$5,195 | — | — | $21,204 | $23,632 |
| Free cash flow | -$961,346 | -$978,149 | -$812,382 | -$1.46M | — | — | -$1.25M | -$984,848 |
| Investing cash flow | -$14,305 | -$12,370 | $0 | $5,195 | — | — | -$521,204 | -$23,632 |
| Financing cash flow | $855,000 | $900,000 | $995,000 | $711,750 | -$348,081 | $4.71M | $1.95M | $887,500 |
| Depreciation & amortization | $13,836 | $134,671 | $135,207 | $14,059 | $17,661 | $117,890 | $75,976 | $30,695 |
| Stock-based compensation | $134,564 | $460,609 | $478,837 | $568,459 | $92,728 | $133,197 | $90,278 | $315,806 |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.